Cefovecin
| Structural formula | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||
| General | |||||||||||||
| Non-proprietary name | Cefovecin | ||||||||||||
| other names |
(6 R , 7 R ) -7 - {[(2 Z ) - (2-Aminothiazol-4-yl) - (methoxyimino) acetyl] amino} -8-oxo-3 - [(2 S ) -tetrahydrofuran-2 -yl] -5-thia-1-azabicyclo [4.2.0] oct-2-en-2-carboxylic acid |
||||||||||||
| Molecular formula | C 17 H 19 N 5 O 6 S 2 | ||||||||||||
| External identifiers / databases | |||||||||||||
|
|||||||||||||
| Drug information | |||||||||||||
| ATC code | |||||||||||||
| Drug class | |||||||||||||
| properties | |||||||||||||
| Molar mass | 453.49 g · mol -1 | ||||||||||||
| safety instructions | |||||||||||||
|
|||||||||||||
| As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . | |||||||||||||
Cefovecin (trade name Convenia ; manufacturer Pfizer ) is a drug from the group of β-lactam antibiotics that is used in veterinary medicine as an injection preparation for dogs and cats for the systemic treatment of infections.
Clinical information
Application areas (indications)
Cefovecin is a β-lactam antibiotic , belongs to the third generation cefalosporins and has a wide therapeutic range against gram-positive and gram-negative pathogens. Against Pseudomonas aeruginosa and Enterococci spp. cefovecin has no antibacterial effect. Due to the high protein binding , cefovecin remains in the body for a long time and has a long plasma half-life .
dog
Cefovecin is primarily used to treat urinary tract, soft tissue and skin infections in dogs. Pyoderma, wounds and abscesses
- Staphylococcus aureus , Staphylococcus intermedius , Pasteurella multocida , Escherichia coli , β-hemolytic streptococci
Urinary tract infections
- Staphylococcus intermedius , Proteus mirabilis , Escherichia coli
cat
In cats, cefovecin is used to treat infections of the skin, soft tissues and urinary tract. Wounds and abscesses
- Pasteurella multocida , Staphylococcus intermedius , β-hemolytic streptococci, Prevotella orali , Fusobacterium spp., Bacteroides spp.
Urinary tract infections
- Escherichia coli
Drug interactions
With the simultaneous application of other drugs with a high protein binding , such as non-steroidal anti-inflammatory drugs (NSAIDs) , ketoconazole , furosemide , there is a competitive displacement of cefovecin. This results in a higher renal excretion, a reduced elimination half-life and thus a shortened duration of action.
Pharmacological properties
The medicinal product, consisting of powder and solvent, contains cefovecin, a β-lactam antibiotic from the group of third-generation cephalosporins , which is administered as a single subcutaneous injection at a dose of 8 mg cefovectin per kg body weight. Cefovecin has a low volume of distribution (0.1 l / kg in dogs; and 0.09 l / kg in cats), with high protein binding, resulting in a very long elimination half-life of around 7 days and an extremely long duration of action of up to 14 Days results.
The indication is formulated restrictively with a view to the importance of the use of antimicrobial substances in veterinary medicine for the development and spread of antibiotic resistance : Use should only be made after a susceptibility test has been carried out and only in the case of infections that are more antimicrobial to other classes They respond poorly to drugs or to first generation cephalosporins.
In Germany, the drug requires a prescription, in Switzerland it has been approved in sales category A (pharmacies with stricter veterinary prescription requirements).
Other Information
Chemical and pharmaceutical information
Cefovecin belongs to the 3rd generation cephalosporins and is a weak base with good water solubility. The sodium salt (CAS number 141195-77-9) has the empirical formula : C 17 H 18 N 5 Na O 6 S 2 with the molar mass of 475.47 g · mol -1 . Cefovecin sodium is freely soluble in various buffer solutions and has maximum stability at a pH value of 6-8. Due to the hygroscopic nature of cefovecin sodium, it should be stored absolutely dry.
Studies
- In vitro activity of difloxacin against canine bacterial isolates J Vet Diagn Invest 12: 218–223 (2000) (PDF; 58 kB)
- In Vitro and In Vivo Activities of LB10522, a New Catecholic Cephalosporin Antimicrobial Agents and Chemotherapy , Aug. 1996, pp. 1825–1831 (PDF; 269 kB)
- Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains Antimicrobial Agents and Chemotherapy, Aug. 2005, pp. 3501–3512 (PDF; 88 kB)
Individual evidence
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
- ↑ a b Convenia - Description of the EMEA .
- ↑ Classification according to the consensus conference of the Paul Ehrlich Society ( Memento from September 18, 2012 in the Internet Archive ).
- ^ Antimicrobial Activity and Spectrum of Cefovecin, a New Extended-Spectrum Cephalosporin, against Pathogens Collected from Dogs and Cats in Europe and North America Antimicrobial Agents and Chemotherapy, July 2006, pp. 2286-2292, Vol. 50, no. 7 (full text).
- ↑ Swissmedic: Authorization of a medicinal product with a new active ingredient: Convenia ad us. vet., Injection preparation (cefovecin) ( Memento from March 4, 2016 in the Internet Archive ) .
Web links
- Entry on cefovecin at Vetpharm, accessed on November 21, 2011.
